FINASTERID - search results

Australia - English - Department of Health (Therapeutic Goods Administration)

aurobindo finasteride finasteride 5 mg tablet blister pack

arrotex pharmaceuticals pty ltd - finasteride, quantity: 5 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; lactose monohydrate; pregelatinised maize starch; magnesium stearate; microcrystalline cellulose; docusate sodium; titanium dioxide; hypromellose; hyprolose; purified talc; iron oxide yellow; indigo carmine aluminium lake - aurobindo finasteride is indicated for the treatment of patients with symptomatic benign prostatic hyperplasia (bph) with an enlarged prostate.

United States - English - NLM (National Library of Medicine)

finasteride tablet film coated

unit dose services - finasteride (unii: 57gno57u7g) (finasteride - unii:57gno57u7g) - finasteride 5 mg

United States - English - NLM (National Library of Medicine)

finasteride tablet, film coated

avpak - finasteride (unii: 57gno57u7g) (finasteride - unii:57gno57u7g) - finasteride tablets usp, are indicated for the treatment of symptomatic benign prostatic hyperplasia (bph) in men with an enlarged prostate to: -improve symptoms -reduce the risk of the need for surgery including transurethral resection of the prostate (turp) and prostatectomy. finasteride tablets usp administered in combination with the alpha-blocker doxazosin is indicated to reduce the risk of symptomatic progression of bph (a confirmed ≥4 point increase in american urological association (aua) symptom score). finasteride tablets usp are not approved for the prevention of prostate cancer. finasteride tablets usp are contraindicated in the following: • hypersensitivity to any component of this medication. • pregnancy . finasteride use is contraindicated in women when they are or may potentially be pregnant. because of the ability of type ii 5α-reductase inhibitors to inhibit the conversion of testosterone to 5α-dihydrotestosterone (dht), finasteride may cause abnormalities of t

United States - English - NLM (National Library of Medicine)

finasteride tablet, film coated

aphena pharma solutions - tennessee, llc - finasteride (unii: 57gno57u7g) (finasteride - unii:57gno57u7g) - finasteride tablets are indicated for the treatment of symptomatic benign prostatic hyperplasia (bph) in men with an enlarged prostate to: - improve symptoms - reduce the risk of acute urinary retention - reduce the risk of the need for surgery including transurethral resection of the prostate (turp) and prostatectomy. finasteride tablets administered in combination with the alpha-blocker doxazosin is indicated to reduce the risk of symptomatic progression of bph (a confirmed ≥4 point increase in american urological association (aua) symptom score). finasteride tablets are not approved for the prevention of prostate cancer. finasteride tablets are contraindicated in the following: - hypersensitivity to any component of this medication. - pregnancy. finasteride use is contraindicated in women when they are or may potentially be pregnant. because of the ability of type ii 5α-reductase inhibitors to inhibit the conversion of testosterone to 5α-dihydrotestosterone (dht), finasteride may cause abnormalitie

United States - English - NLM (National Library of Medicine)

finasteride tablet, film coated

nucare pharmaceuticals,inc. - finasteride (unii: 57gno57u7g) (finasteride - unii:57gno57u7g) - finasteride tablets usp, are indicated for the treatment of symptomatic benign prostatic hyperplasia (bph) in men with an enlarged prostate to: -improve symptoms -reduce the risk of the need for surgery including transurethral resection of the prostate (turp) and prostatectomy. finasteride tablets usp administered in combination with the alpha-blocker doxazosin is indicated to reduce the risk of symptomatic progression of bph (a confirmed ≥4 point increase in american urological association (aua) symptom score). finasteride tablets usp are not approved for the prevention of prostate cancer. finasteride tablets usp are contraindicated in the following: • hypersensitivity to any component of this medication. • pregnancy . finasteride use is contraindicated in women when they are or may potentially be pregnant. because of the ability of type ii 5α-reductase inhibitors to inhibit the conversion of testosterone to 5α-dihydrotestosterone